Ding, X., Bai, X., Wang, Z., Li, X., Hu, N., Wu, S. (2026). Disitamab vedotin plus PD-1 inhibitors as neoadjuvant therapy for cisplatin-ineligible muscle-invasive bladder cancer: A real-world retrospective study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.691